Bealtaine 2022: Féadfaidh Trametinib a bheith ina chaighdeán nua cúraim d’ailse ovarian serous athfhillteach de ghrád íseal (Meicinist). According to study findings published in the February 2022 issue of The Lancet, trametinib beat both chemotherapy and anti-estrogens like tamoxifen by around 52 percent, adding six months of progression-free (period during which the cancer did not advance) survival for patients.
I 260 mná le siadaí ovarian serous athfhillteach a fuair ceimiteiripe roimhe seo, chuir taighdeoirí ó na Stáit Aontaithe agus an Ríocht Aontaithe i gcomparáid le trametinib béil uair sa lá le ceann de chúig réimeas cúraim chaighdeánach (ceachtar ceimiteiripe nó cógais frith-estrogen). I gcomparáid leis an gcóireáil is gnách, léirigh rannpháirtithe trametinib freagra ceithre huaire níos airde ar theiripe tar éis 15 mhí. D'fheidhmigh Trametinib níos fearr ná gach cóireáil eile, rud a chuir moill ar dhul chun cinn an ghalair ar feadh 13 mhí (i gcomparáid le seacht mí le haghaidh cóireála caighdeánach). Tá gríos craicinn, ainéime, brú fola ard, buinneach, agus tuirse ar chuid de na héifeachtaí díobhálacha a d’fhéadfadh a bheith contúirteach a bhaineann le cóireáil trametinib.
Low-grade serous ailse ovarian is a difficult-to-treat invasive form of ovarian cancer marked by strong hormone receptor activation, genetic alterations, and poor chemotherapy response. Until now, the cancer toolbox lacked effective therapeutic options for patients with low-grade serous ovarian cancer. According to an editorial accompanying the report, 70% of these women will recur, with only 5% responding to further chemotherapy.
